SCHEMBL8656153

SCHEMBL8656153

CCOC(=O)CC1CCc2cc3ccccc3n2C1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 4/20 0.41
HTR2C P28335 4/20 0.41
ALDH1A1 P00352 3/20 0.39
SIGMAR1 Q99720 2/20 0.38
KDM4E B2RXH2 4/20 0.37
NOD2 Q9HC29 2/20 0.37
NOD1 Q9Y239 2/20 0.37
HSD17B10 Q99714 2/20 0.37
HPGD P15428 1/20 0.37
TSHR P16473 1/20 0.37
SAE1 Q9UBE0 1/20 0.37
UBA2 Q9UBT2 1/20 0.37
PSMD14 O00487 1/20 0.37
GAA P10253 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
PARP14 Q460N5 1/20 0.37
RAB9A P51151 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8328343 0.81 ALDH1A1 (0.45) HTR2AHTR2CALDH1A1KDM4EHSD17B10
SCHEMBL8653456 0.79 HTR2A (0.39) HTR2AHTR2CSIGMAR1
SCHEMBL8657721 0.75 ALDH1A1 (0.49) HTR2AHTR2CALDH1A1KDM4EHSD17B10
SCHEMBL8654307 0.75 HTR2A (0.43) HTR2AHTR2CSIGMAR1
SCHEMBL8447552 0.73 ALDH1A1 (0.44) ALDH1A1KDM4EHSD17B10MEN1KMT2A
SCHEMBL8657832 0.73 SIGMAR1 (0.45) HTR2AHTR2CSIGMAR1
SCHEMBL8450915 0.72 HTR2A (0.43) HTR2AHTR2CSIGMAR1
SCHEMBL8658423 0.72 HTR2A (0.43) HTR2AHTR2CSIGMAR1
SCHEMBL21027979 0.72 HTR2A (0.43) HTR2AHTR2CALDH1A1SIGMAR1TSHR
SCHEMBL8655471 0.71 DRD2 (0.38) HTR2AHTR2CSIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11524958-B2 Tricyclic compound as CRTH2 inhibitor CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2022-12-13 US disclosed
US-20210403466-A1 TRICYCLIC COMPUND AS CRTH2 INHIBITOR CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2021-12-30 US disclosed
EP-3489235-A1 TRICYCLIC COMPOUND AS CRTH2 INHIBITOR Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) 2019-05-29 EP disclosed
US-5721245-A ANTIINFLAMMATORY AGENTS, RESPIRATORY SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS HOFFMANN-LA ROCHE INC. (US) 1998-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210403466-A1 TRICYCLIC COMPUND AS CRTH2 INHIBITOR NR3C2, CRHR2, CRHR1 HTR2A 604/4885HTR2C 749/4885ALDH1A1 3257/4885
US-11524958-B2 Tricyclic compound as CRTH2 inhibitor NR1H2, NR3C2, NR1H4 HTR2A 772/4885HTR2C 1011/4885ALDH1A1 3139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.